Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin's lymphoma typically marked by an aggressive clinical course and a predilection for relapse. The B-cell receptor (BCR) signaling survival pathway is chronically activated in MCL, contributing to its pathogenesis. Ibrutinib is an inhibitor of Bruton's tyrosine kinase, a vital component of this pathway. This article details the current clinical experience with ibrutinib in the treatment of patients with MCL, including completed and published clinical trials and reviews potential adverse events (AEs) and pitfalls associated with ibrutinib therapy. Although most AEs experienced by patients treated with ibrutinib are mild, some can be severe and treatment limiting and may be attributed to off-target effects. Ibrutinib is a very promising agent for patients with MCL with notable response rates. However, when used as a single agent, around one third of patients relapse in the first 2 years of treatment. Recently reported combination therapies have shown significant activity. Emerging data evaluating potential mechanisms of drug resistance and the poor clinical outcomes after treatment failure are also discussed. Further understanding of resistance and its implications not only in relapsed disease but in the frontline setting are needed. Investigation of strategies to overcome resistance remains an area of high unmet clinical need. Evaluation of the impact of shorter treatment duration, effects on minimal residual disease, and incorporation of novel combinations are also warranted.
Introduction
Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin's (NHL) B-cell lymphoma defined by cyclin D1 overexpression or t (11;14) . MCL often follows an aggressive clinical course with an overall poor prognosis. Young, fit patients are typically treated with chemoimmunotherapy commonly followed by autologous stem-cell transplant (SCT) [Geisler et al. 2008; Romaguera et al. 2010; Merli et al. 2012; Le Gouill et al. 2014 ]. However, the average age of a patient diagnosed with MCL is 68 years [Zhou et al. 2008 ], a group in whom medical comorbidities often play a role during therapy. Therefore, alternative and more tolerable chemoimmunotherapeutic regimens such as bendamustine and rituximab (BR) [Rummel et al. 2013; Flinn et al. 2014] or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) with rituximab maintenance [Kluin-Nelemans et al. 2012 ] are commonly used for frontline therapy in this population. Despite high overall response rates (ORRs) with initial therapy, most patients will eventually relapse and die from their disease. Over the past decade, clinical outcomes appear to have improved, with studies suggesting improved overall survival (OS) among certain cohorts [Herrmann et al. 2009; Chandran et al. 2012 ]. However, despite the incorporation of aggressive upfront therapeutic strategies and introduction of novel agents, no plateau in survival curves has been appreciated and late relapses even after 5 years of remission can be seen [Romaguera et al. 2010; Geisler et al. 2012; Robak et al. 2015] . There is a clear need for novel and more effective therapeutic options for patients with MCL.
Chronic active signaling via the B-cell receptor (BCR) pathway has been implicated in the pathogenesis of many subtypes of B-cell malignancies, including MCL. Overexpression of an integral protein in the BCR pathway, Bruton's tyrosine kinase (BTK), has been observed in MCL cell lines and patient samples [Rinaldi et al. 2006; Cinar et al. 2013 ]. Activation of BTK and its downstream targets plays a vital role in normal and malignant B cells, including modulation of nuclear transcription, as well as regulation of B-cell proliferation, differentiation, survival and migration [Herrera and Jacobsen, 2014] . In MCL, phosphoproteomic analysis of cell lines indicate a prosurvival role of BCR signaling in this malignancy [Pighi et al. 2011] . The importance of BCR signaling pathway proteins in B-cell malignancy pathogenesis has driven interest in using inhibitors of these proteins as therapeutic options.
Ibrutinib is a potent, orally bioavailable inhibitor of BTK that binds irreversibly to a cysteine residue (C481) in the BTK active site. In preclinical studies in MCL cell lines, ibrutinib demonstrated inhibition of downstream BCR signaling and cell apoptosis [Cinar et al. 2013] . In preclinical animal studies, eight dogs with spontaneous canine B-cell lymphoma were safely treated with ibrutinib. Single administration of 2.5-20 mg/kg per day was sufficient to fully occupy BTK in peripheral blood and tumor tissue for 24 h. Three dogs obtained a partial response (PR) and three dogs maintained stable disease (SD) [Honigberg et al. 2010] . With preclinical safety data completed, ibrutinib moved into clinical trials in humans. The purpose of this review is to discuss the clinical experience using ibrutinib in patients with MCL and to identify potential pitfalls, therapeutic challenges, and opportunities in the era of targeted agents. Given its impressive clinical activity, ibrutinib has now been approved by the US Food and Drug Administration (FDA) for relapsed/refractory MCL, chronic lymphocytic leukemia (CLL) and Waldenstrom's macroglobulinemia (WM) and frontline in patients with CLL with del(17p13.1) karyotype and WM.
Clinical experience with ibrutinib in the treatment of patients with MCL
Ibrutinib single-agent therapy in patients with relapsed and refractory MCL Even in early phase clinical trials, it was clear that ibrutinib brought promising efficacy to patients with relapsed/refractory (R/R) MCL. An initial phase I multicenter study treated 56 patients with R/R B-cell NHL with single-agent ibrutinib via multiple dosing schemes. Among the nine patients with MCL on this trial, seven achieved response (three CRs). Most adverse events (AEs) were grade 1-2 with the most common AEs of diarrhea, nausea, fatigue, and myalgia. Grade 3-4 AEs were rare and most commonly included cytopenias (<15%). The dose of 560 mg by mouth daily was well tolerated and led to fulltarget occupancy in a range of individual body weights and therefore was chosen for phase II study [Advani et al. 2013 ].
In the pivotal phase II trial that led to FDA approval of ibrutinib in R/R MCL, 111 patients with MCL received single-agent ibrutinib (560 mg daily). The median age of the patients in the study was 68 years (range 40-84) and therefore representative of the typical MCL patient population. The ORR was 68% with a CR rate of 21%. Again, the most common grade 1-2 AEs were diarrhea, nausea, and fatigue. Grade 3-4 cytopenias were less than 20% (most commonly neutropenia). After initial follow-up of 15.3 months, the estimated median progression-free survival (PFS) was 13.9 months [95% confidence interval (CI) 7.0-not reached], and the estimated OS was not reached [Wang et al. 2013 ]. However, with an extended median follow up of 26.7 months, the estimated median PFS was 13 months with approximately one third of patients failing to respond to therapy at 2 years. The median OS was 22.5 months [Wang et al. 2014b ].
Prior to ibrutinib's FDA approval in MCL, 149 patients with R/R MCL were enrolled on an open-label early-access treatment protocol using single-agent ibrutinib. The median age of patients in this study was also 68 years (range 39-90). Of these patients, 58.5% had refractory disease and 66.7% had received at least three prior lines of therapy. Grade 3-4 AEs were observed in 39.6% of the patients, the most common of which was cytopenia (<10%). AEs of particular interest were one patient with a major hemorrhage and one patient with intracranial bleeding. Long-term follow up has yet to be reported; however, two thirds of the patients in the trial were still taking ibrutinib at study completion (US FDA approval) [Martin et al. 2014a ].
Ibrutinib combination therapy in patients with MCL
In order to improve upon the promising efficacy of ibrutinib as a single agent in the treatment of patients with MCL, many investigators sought to combine this agent with other therapies (Table 1) . Rituximab is a monoclonal antibody that targets CD20, which is used widely in CD-20-positive B-cell malignancies. Rituximab has been studied in combination with ibrutinib in patients with several B-cell malignancies, including MCL. In preclinical studies, concerns arose that off-target effects of ibrutinib may limit the effectiveness of rituximab when used in combination. Specifically, preclinical studies in CLL indicate that ibrutinib may decrease the CLL cell surface expression of CD20 [Bojarczuk et al. 2014] and may decrease or ablate the antibody-dependent cell-mediated cytotoxicity of monoclonal antibodies [Kohrt et al. 2014 ] via off-target inhibition of interleukin-2-inducible kinase (ITK) in natural killer (NK) cells [Dubovsky et al. 2013] . Despite these concerns, clinical trials with the combination moved forward. In a phase II study, 50 patients with R/R MCL were treated with rituximab (375 mg/m 2 intravenously weekly × 4, then monthly for up to 2 years) and ibrutinib (560 mg orally daily). With a median follow up of 6.5 months (range 1-10), the ORR was 87% with 38% CR rate. All patients with SD or progressive disease had a proliferation index (Ki67) of at least 50%. Of the 33 patients with Ki67 less than 50%, the ORR was 100% with a 48% CR rate. These data suggest that this regimen may be more effective in patients without the blastoid variant, which often is associated with high Ki67. However, the clinical and biologic relevance of this finding should be interpreted with caution given that a Ki67 cutoff of 50% is high by MCL standards and likely the result of trying to stratify outcomes using a relatively small dataset. Grade 3 AEs were neutropenia (1) and thrombocytopenia (1). Notably six patients developed atrial fibrillation (afib) [Wang et al. 2014a] . A similar ongoing phase II trial pairs ibrutinib with ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody in patients with R/R MCL and CLL [ClinicalTrials.gov identifier: NCT02013128]. Early analysis suggests this combination is active and well tolerated in patients with MCL .
Chemoimmunotherapy regimens using cytotoxic chemotherapy plus rituximab and ibrutinib is also an area of active study. Bendamustine is an alkylating agent with efficacy in MCL that is commonly used in combination with rituximab, demonstrating ORR greater than 90% . A phase I/Ib study evaluated the safety of bendamustine (90 mg/m 2 on days 1 and 2 for six cycles) and rituximab (375 mg/m 2 on day 1 for six cycles) with ibrutinib (280 or 560 mg daily indefinitely) in 48 patients with NHL. Of these patients, 17 had MCL (previously untreated = 5). No doselimiting toxicities (DLTs) were observed. The most common grade 3/4 AEs were cytopenias and rash. Among the patients with MCL the ORR was 94% with a 76% CR rate [Maddocks et al. 2015 ]. An ongoing randomized international study, which recently closed to accrual investigates this combination (followed by 2 years of maintenance rituximab) in patients over the age of 65 with newly diagnosed MCL (SHINE study) [ClinicalTrials.gov identifier: NCT01776840]. Similarly, RCHOP chemotherapy has long been used to treat MCL with significant efficacy ]. Another phase Ib study attempted to safely combine RCHOP with ibrutinib in 33 patients with treatment-naïve NHL, including five patients with MCL. Of all patients, the most common grade 3 AEs were cytopenias. The group as a whole demonstrated an ORR of 94% with a 72% CR rate. No specific response data for the patients with MCL were included [Younes et al. 2014] . Without a randomized phase III trial for patients with previously treated indolent MCL, it is unclear whether the combination of ibrutinib with either BR or RCHOP is superior. In an effort to define the contribution of ibrutinib to aggressive induction strategies, the European MCL Network is sponsoring the Triangle Study which randomizes patients with MCL to one of three arms: RCHOP alternating with rituximab, dexamethasone, cytarabine, and cisplatin (RDHAP) followed by autologous SCT; RCHOP/RDHAP with ibrutinib followed by autologous SCT with ibrutinib maintenance; and RCHOP/RDHAP with ibrutinib followed by ibrutinib maintenance. Another trial that uses ibrutinib as maintenance therapy for patients with MCL following various induction therapies including BR and RCHOPbased regimens is open for accrual [ClinicalTrials. gov identifier: NCT02242097]. These studies attempt to address how to best use ibrutinib with chemoimmunotherapy regimens.
Lenalidomide is an oral immunomodulatory agent with single-agent activity in R/R NHL, including MCL [Habermann et al. 2009; Goy et al. 2013; Zinzani et al. 2013] . A phase I study for patients with R/R NHL combining lenalidomide with ibrutinib has been reported. At the date of the last report, 13 patients had been treated (two patients with MCL). At the first dose level (DL1) of lenalidomide 15 mg and ibrutinib 420 mg, two DLTs 
Other combinations with ibrutinib in patients with MCL
Multiple other combination clinical trials or trial concepts are in various stages of development and implementation, which are described in Table 2 .
Pitfalls in the use of ibrutinib for patients with MCL
Despite the notable clinical efficacy of ibrutinib in the treatment of patients with MCL, there are features about the drug that may affect the drug's future development or use in the clinic, including cost, off-target effects, drug interactions, and development of resistance.
AEs related to off-target effects of ibrutinib
In addition to inhibition of BTK, ibrutinib can also inhibit other kinases with similar cysteine residues at their active sites, such as ITK, epidermal growth factor receptor (EGFR), tyrosine protein kinase (TEC), B-lymphocyte kinase (BLK), epithelial/ endothelial tyrosine kinase (BMX), human epidermal growth factor 2 receptor (HER2), and human epidermal growth factor 4 (HER4), among others [Herrera and Jacobsen, 2014; Woyach et al. 2014] , which may lead to off-target side effects. ITK normally drives proximal T-cell receptor signaling and positively regulates NK cell's Fc Receptor-initiated cytotoxicity via recognition of antibody-coated targets [Khurana et al. 2007] . Ibrutinib has been shown to irreversibly inhibit ITK [Dubovsky et al. 2013] , which in preclinical models, has been shown to limit the therapeutic activity of monoclonal antibody therapies through ablation of antibodydependent NK-cell-mediated cytotoxicity [Kohrt et al. 2014 ]. However, given the impressive clinical activity seen with ibrutinib in combination with rituximab [Wang et al. 2014a ] this finding may not be clinically significant. Furthermore, this effect may not be as relevant in the novel Fc-engineered type II antibodies such as obinutuzumab [Da Roit et al. 2015] . In addition to potentially interfering with the clinical efficacy of anti-CD20 therapy, inhibition of ITK may have additional clinical consequences. The majority of patients with a rare genetic ITK deficiency syndrome develop severe Epstein Barr virus infections that can lead to fatal lymphoproliferative disorders [Huck et al. 2009 ]. Although this warrants mention, especially as more patients are subjected to prolonged ITK inhibition, to date, this has not been widely reported in patients receiving ibrutinib.
Ibrutinib has been shown to inhibit EGFR [Gao et al. 2014 ]. EGFR-inhibiting agents are currently used in the treatment of multiple types of solid tumors. As there are high levels of EGFR expression in the basal layer of the epidermis [Nanney et al. 1984] and normal gastrointestinal mucosa , the most common AEs demonstrated by patients treated with EGFR-inhibiting agents are skin rashes and diarrhea. Thus, the skin rashes and diarrhea commonly seen in patients treated with ibrutinib are not surprising [Byrd et al. 2013 , Wang et al. 2014b ]. Similar to other EGFR inhibitors, ibrutinib-related rashes should be managed according to the severity of the reaction. For example, localized reactions with no physical symptoms can be managed with topical low-potency steroid (1% hydrocortisone) or topical antibiotics (2% clindamycin). Moderate reactions (those with systemic symptoms) can be treated with topical treatments and the addition of an oral tetracycline antibiotic (doxycycline 100 mg daily or minocycline 100 mg twice daily for 4 weeks). Severe reactions should be managed with at least temporary discontinuation of the drug and use the preceding treatment options [Melosky and Hirsh, 2014] . Ibrutinib can potentially be restarted with a dose reduction if the rash has decreased to at least moderate severity. The other EGFR inhibitor-related side effect, diarrhea, is most likely to occur in the first 4 weeks after treatment initiation, and importantly, the risk seems to diminish over time. Around half of ibrutinibtreated patients will experience diarrhea, the majority of which is grade 1-2. The diarrhea is thought to be primarily secretory, although the mechanism is unclear ]. Similar to management of EGFR inhibitor related diarrhea, management of patients with ibrutinib-induced diarrhea should include patient education, nonpharmacologic management strategies (including dietary change and increased fluid intake), pharmacologic management strategies (most commonly loperamide), or temporary drug discontinuation for grade 3 diarrhea (at least seven stools daily or interfering with activities of daily living).
Other AEs reported in up to 50% of ibrutinibtreated patients were various severities of bleeding. Most events were grade 1/2 (spontaneous bruising or petechiae), but in 5% of the patients, the events were grade 3 or higher following trauma [Advani et al. 2013; Byrd et al. 2013; Wang et al. 2014b] . In vitro, ibrutinib has been shown to inhibit BTK and TEC kinase leading to inhibition of GPV1-and GP1b-mediated platelet function, which essentially inhibits platelet aggregation, resulting in decreased platelet adhesion on von Willebrand factor [Levade et al. 2014 ]. The noted bleeding AEs in clinical trials have led to restriction of patients' use of anticoagulants, specifically warfarin, while on ibrutinib studies. Importantly, since the majority of bleeding is minor, it can be managed without significant treatment interruptions or dose modifications. However, this side effect can be particularly concerning for patients, and as such, they should be counseled on this potential AE. Of note, although not reported in clinical studies, in our experience of using ibrutinib, we have also seen bleeding in somewhat atypical sites, including recurrent spontaneous hemotypanum and hemothorax. Of note, patients with NHL and CLL are typically older and may require ongoing anticoagulation, which may limit the use of ibrutinib in these patients. No data exist detailing the safety of the combination of the new oral anticoagulants and ibrutinib. Therefore, whenever possible, anticoagulation should be avoided in patients on ibrutinib. However, if required, we preferentially use low-weight molecular heparin (typically enoxaparin) as it is short acting and its effects can be reversed in the event of bleeding. In patients without other viable clinical options, we have also successfully and safely treated a number of patients with oral direct thrombin inhibitors in combination with full-dose ibrutinib, noting that patients should be counseled extensively on potential risks and this approach should be done with caution, especially in patients with underlying thrombocytopenia. In addition, although the use of antiplatelet agents, such as aspirin and clopidogrel, are not absolutely contraindicated, we recommend discontinuing their use unless these agents are deemed absolutely necessary. In the event of a bleeding episode, platelet transfusion has been shown to correct aberrant ibrutinib-related hemostasis [Levade et al. 2014 ]. If a patient requires minor or major surgery, we follow the package insert which recommends abstention from ibrutinib for 3 to 7 days before and after a minor or major procedure, respectively.
Another AE that has been attributed to ibrutinib in multiple clinical trials which was most notable in the RESONATE study, a phase III clinical trial comparing ibrutinib with ofatumumab (anti-CD20 monoclonal antibody) in patients with CLL ] is afib. Five percent of patients receiving ibrutinib (3% were grade ⩾ 3) developed afib compared with less than 1% of patients who received ofatumumab (none were grade ⩾ 3). The mechanisms for this AE have not been well defined; however, a preclinical mouse model suggested that afib may be induced by inhibition of phosphatidylinositol 3-kinase p110-α (PI3K; another important member of the BCR signaling pathway) in cardiac myocytes [McMullen et al. 2014] . The authors of this study concluded that the patients who received ibrutinib on RESONATE may have been at a higher baseline risk for afib. Accordingly, although a further understanding of the potential risks of afib with ibrutinib is needed, afib is not an absolute contraindication to treatment with ibrutinib, and the development of afib does not require discontinuation of ibrutinib as the risk usually does not outweigh ibrutinib's clinical benefit. However, given potential drug interactions, pharmacologic cardioversion in patients receiving ibrutinib should only be considered after discussions with a pharmacist and such patients should be monitored closely. As mentioned previously, if a patient requires anticoagulation for afib, one should proceed with caution.
Studies using ibrutinib have not extensively evaluated interruption of therapy. Instead, studies have required continuous dosing even after remission has been achieved. Given the potential toxicities described above as well as the financial burden (>$10,000 per month) of ongoing therapy, studies are needed to evaluate shorter durations of therapy, depth of response (i.e. ability to achieve minimal residual disease negativity), and planned dose interruptions in responding patients. Secondary to the clinical impact of off-target side effects of ibrutinib, second generation and more specific BTK inhibitors, such as ACP-196, have been developed and are in various stages of clinical trials.
[ClinicalTrials.gov identifier: NCT02213926], CC-292, and ONO-4059 [ClincalTrials.gov identifier: NCT01659255]. Although at an earlier stage of clinical development, CC-292 treatment has resulted in similar toxicity profile with diarrhea as the most common AE [Brown et al. 2013] .
Results for clinical trials with ACP-196 have yet to be reported to demonstrate if improved binding specificity will ablate some of the off-target AEs seen with ibrutinib without compromising efficacy.
Drug interactions with ibrutinib
Drug interactions must also be analyzed carefully when considering ibrutinib treatment. The drug is metabolized in the liver by cytochrome P450 3A4 (CYP3A4), which can result in drug interactions with inducers or inhibitors of CYP3A4 [Herrera and Jacobsen, 2014] . Notable inhibitors of CYP3A4 are grapefruit juice, azole antifungal agents, anti-human immunodeficiency virus agents, metronidazole, ciprofloxacin, and tetracycline. Notable inducers of CYP3A4 are antiseizure medications (carbamazepine, oxycarbazepine, fosphenytoin, phenytoin, pentobarbital, and phenobarbital). Prior to initiation of ibrutinib, a careful review of current medications with changes to potential interacting drugs is required for patient safety.
Relapses after and refractoriness to ibrutinib Acquired and primary resistance have been seen in patients with MCL treated with ibrutinib, and these patients have demonstrated poor clinical outcomes. Similar to chronic myelogenous leukemia, where acquired resistance can be seen after prolonged tyrosine kinase inhibitor therapy [O'Dwyer et al. 2004] , prolonged therapy with ibrutinib can lead to resistance via prevention of irreversible binding of BTK. For example, Chiron and colleagues evaluated serial biopsies in ibrutinib-treated patients with MCL. Two of seven patients with acquired resistance to ibrutinib (who had attained PR on therapy with duration of response of 14 and 30 months, respectively), were found to have a cysteine to serine mutation at the BTK binding site of ibrutinib (BTK C481S ), which decreases ibrutinib's binding affinity, rendering it ineffective [Chiron et al. 2014] . Importantly, these mutations were not identified prior to ibrutinib treatment. The same mutation was first described in patients with CLL with acquired resistance to ibrutinib [Woyach et al. 2014] . Conversely, the BTK C481S mutation was not found in six patients with MCL with primary or early acquired resistance to ibrutinib (on therapy for < 5 months) [Chiron et al. 2014] . In these patient samples, the investigators found that downstream kinases in the BCR signaling pathway were activated, specifically PI3K and protein kinase B (AKT). Similarly, another group found that in MCL cell lines, ibrutinib resistance may be caused by activation of the alternative nuclear factor light-chain enhancer of activated B cells (NFκB) pathway (via MAP3K14), whereas the pathogenesis of ibrutinib-sensitive MCL cell lines depends upon the classical BCR-BTK-NFκB pathway [Rahal et al. 2014] . Patient data support the role of the NFκB pathway in primary ibrutinib resistance. In a phase II study in which 110 patients with MCL R/R after rituximab containing chemotherapy and bortezomib therapy received single-agent ibrutinib (SPARK Trial) [ClinicalTrials.gov identifier: NCT01599949], 25 patients were considered to have primary treatment resistance and another 22 patients were classified as having moderate clinical benefit defined as SD (n = 16) or response lasting less than 12 months (n = 6). Interestingly, only 20% of the patients with primary resistance were deemed to have blastic MCL, an aggressive subtype of MCL associated with poor outcomes, while 38% had a high mantle cell international prognostic index. In an attempt to identify potential genetic aberrations associated with ibrutinib resistance, DNA was extracted from pretreatment tumor samples and enriched libraries were constructed with probe sets specific for the coding region of 97 genes possibly involved in ibrutinib response and resistance. Deep sequencing was performed and aligned to the reference genome. A total of 27 genes were found with nonsynonymous variants in at least two patients. No mutations previously described in patients with MCL or CLL and acquired resistance to ibrutinib were seen. Genes previously implicated in diffuse large B-cell lymphoma (DLBCL) pathogenesis such as mixed lineage leukemia protein 2 (MLL2) and cAMP response element binding protein (CREBBP) were mutated along with mutation in protooncogene serine/threonine-protein kinase (PIM1) and erb-b2 receptor tyrosine kinase 4 (ERBB4) kinase genes. Several of the mutations detected affect NFκB signaling inhibition, which is an integral part of the BCR signaling pathway, normally inhibited by ibrutinib [Balasubramanian et al. 2014 ]. These results are hypothesis generating and may implicate important signaling pathways; however, whether the observed mutations are markers of poor risk or drivers of resistance remains unclear.
The outcome of patients with MCL with acquired resistance to ibrutinib is poor. One study describes 42 patients with MCL who discontinued therapy with ibrutinib. Among 31 patients who experienced disease progression following ibrutinib and underwent salvage therapy, the ORR was only 32%. At a median follow up of 10.7 months (range 2.4-38.9 months), the median OS after disease progression was only 8.4 months [Cheah et al. 2015] . Another retrospective, multi-institutional cohort study described 32 patients with MCL who experienced disease progression while receiving ibrutinib. Of the 19 patients who received a salvage therapy after ibrutinib, 17 were evaluable for response and only 6 of those patients (35%) achieved an objective response to subsequent treatment. The median OS following cessation of ibrutinib was only 4 months (95% CI 2-10 months) ]. Analysis of a larger international multicenter cohort of MCL ibrutinib failures is ongoing. These data are in line with what we have seen in the clinic, including the development of aggressive disease and blastoid transformation while on therapy.
It is not yet clear if the poor outcomes seen after ibrutinib failure simply represent the final common pathway of treating patients with advanced MCL or the result of ibrutinib selecting for a biologically more aggressive phenotype, the latter of which could have significant implications given the implementation of ibrutinib in the frontline treatment setting. Further studies to better understand ibrutinib, the mechanisms driving resistance, and how to treat these patients are urgently needed.
Summary
This article details the clinical experience with ibrutinib in the treatment of patients with MCL, including completed and published clinical trials and a review of potential AEs and resistance. Ibrutinib is a promising agent for patients with MCL with notable response rates. However, as a single agent, nearly one third of patients relapse in the first 2 years of treatment, which calls for investigation of combination therapies as well as evaluating the addition of ibrutinib to upfront treatment strategies. Although most AEs experienced by patients treated with ibrutinib are mild, some can be severe and treatment limiting and may be attributed to off-target effects of the drug. Therefore, attempts to develop more specific second-generation BTK inhibitors that may mitigate some of these AEs are underway. Prior to prescribing ibrutinib, a thorough review of a patient's medications should be completed to determine potential drug interactions. Caution should be used when considering ibrutinib for patients requiring chronic anticoagulation, noting that additional studies are needed to better characterize risks in patients on newer anticoagulants.
Patients who develop resistance to ibrutinib demonstrate very poor clinical outcomes. Increasingly, as ibrutinib is studied earlier in the course of the disease, special attention to progression patterns, disease biology, and outcomes after ibrutinib failure will be paramount. Further definition of resistance and investigation of strategies to improve clinical outcomes in these patients remain an area of high unmet clinical need. Evaluation of secondgeneration BTK inhibitors is ongoing. Studies of the impact of shorter treatment duration, effects on minimal residual disease, initiation of therapy on molecular relapse, and incorporation of novel combinations are warranted.
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